YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients

• Type: Article in International Scientific Journal
• Date: 2020

Authors

Afonso, A (Author) Other; Silva, J (Author) Other; Lopes, AR (Author) Other; Coelho, S (Author) Other; Patrao, AS (Author) Other; Rosinha, A (Author) Other; Carneiro, F (Author) Other; Pinto, AR (Author) Other; Mauricio, MJ (Author) Other; Rui Medeiros (Author) ICBAS

Journal

Title: Pharmacogenomics

Vol. 21

Pages: 919-928

ISSN: 1462-2416

Publisher: ASHLEY PUBLICATIONS LTD

Indexing

ISI Web of Knowledge - 3 Citations

Scopus - 2 Citations

Other information

Authenticus ID: P-00S-M31

DOI: 10.2217/pgs-2020-0008

Abstract (EN): Aim:To evaluate the influence ofYB-1 rs10493112 variant as a genetic marker for response to second-generation androgen receptor axis-target agents.Methods:A hospital-based cohort study of 78 patients with metastatic castration-resistant prostate cancer was conducted. Genotyping was performed by TaqMan(R)allelic discrimination technology.Main results:In abiraterone-treated and high-risk patients,YB-1rs10493112 AA genotype carriers showed lower progression-free survival than C allele genotype patients (4 vs 17 months; p = 0.009). For carriers of AA genotype, multivariate Cox regression analysis revealed a fivefold increased risk of progression (p = 0.035).Conclusion:The study findings suggest that, for metastatic and castration-resistant prostate cancer patients, this polymorphism might be a putative marker for the clinical outcome.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 10